ALKINDI Drug Patent Profile
✉ Email this page to a colleague
When do Alkindi patents expire, and when can generic versions of Alkindi launch?
Alkindi is a drug marketed by Eton and is included in one NDA. There are three patents protecting this drug.
The generic ingredient in ALKINDI is hydrocortisone. There are sixty-seven drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the hydrocortisone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Alkindi
A generic version of ALKINDI was approved as hydrocortisone by IMPAX LABS INC on March 30th, 2007.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ALKINDI?
- What are the global sales for ALKINDI?
- What is Average Wholesale Price for ALKINDI?
Summary for ALKINDI
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Prices: | Drug price information for ALKINDI |
| What excipients (inactive ingredients) are in ALKINDI? | ALKINDI excipients list |
| DailyMed Link: | ALKINDI at DailyMed |
US Patents and Regulatory Information for ALKINDI
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eton | ALKINDI SPRINKLE | hydrocortisone | GRANULE;ORAL | 213876-001 | Sep 29, 2020 | RX | Yes | No | 9,717,740 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Eton | ALKINDI SPRINKLE | hydrocortisone | GRANULE;ORAL | 213876-003 | Sep 29, 2020 | RX | Yes | No | 9,717,740 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Eton | ALKINDI SPRINKLE | hydrocortisone | GRANULE;ORAL | 213876-002 | Sep 29, 2020 | RX | Yes | No | 9,675,559 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Eton | ALKINDI SPRINKLE | hydrocortisone | GRANULE;ORAL | 213876-004 | Sep 29, 2020 | RX | Yes | Yes | 9,675,559 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Eton | ALKINDI SPRINKLE | hydrocortisone | GRANULE;ORAL | 213876-003 | Sep 29, 2020 | RX | Yes | No | 9,649,280 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
